Pfizer Expects $100 Billion Grab for AstraZeneca to Boost Pipeline and Drop Tax Rate

SUGAR LAND--April 30, 2014--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Despite a host of headaches, including steep patent losses and an industry in continual reorganization, Pfizer Incorporated (NYSE:PFE) (New York, New York) has managed to remain one of the world's largest drug companies. With revenues of $51.6 billion in 2013, the company is now intent on spending at least $100 billion to snatch up AstraZeneca plc (NYSE:AZN) (London, England).

Other companies featured: Actavis plc (NYSE:ACT), Forest Laboratories Incorporated (NYSE:FRX)